Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of alectinib plus atezolizumab in patients with ALK positive advanced non-small cell lung cancer: A phase Ib study

Trial Profile

Safety and efficacy of alectinib plus atezolizumab in patients with ALK positive advanced non-small cell lung cancer: A phase Ib study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jun 2018 New trial record
    • 05 Jun 2018 Results (n=21; as of 18 Aug 2017) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top